AstraZeneca reports results of subgroup analysis from Phase III FALCON trial

AstraZeneca has reported results from a pre-specified subgroup analysis of the positive Phase III FALCON trial, indicating that treatment effects in terms of progression-free survival (PFS) were mostly consistent across the subgroups analysed with so …

Source: Drug Development Technology - December 12, 2016 Category: Pharmaceuticals Source Type: news